Patients who are to benefit from an injection of SYNOVIUM HCS as part of their care will be offered to participate in this study. Patients will need to sign a consent form to participate. Prior to SYNOVIUM HCS injection, patients will be asked a series of questions regarding their pain and disability. Data collected during follow-up visits can be compared to pre-injection data.

Inclusion period: 6 months

Follow-up period:

• 6-month follow-up, after intra-articular injection with extension

  • 1 single syringe of SYNOVIUM HCS (3 mL),
  • Controls scheduled at 1 week, 1, 3, 6 months and up to 1 year
  • Additional control (single) in the event of leaving the study if this takes place outside the scheduled visit dates and before 1 year, for medical reasons

• Duration of the study: Overall time estimated at 18 months

• In this open-label CI, the group itself is used as a control, by comparing the scores on inclusion with those of the various control visits.

Inclusion Criteria:

• Adult patient
• Patient with radiologically characterized gonarthrosis (stages Kellgren & Lawrence grades I to III)
• Patient with walking pain (WOMAC A1) at least equal to 2 on the Likert scale 0-4
• Patient to benefit from an injection of SYNOVIUM HCS as part of his treatment
• Patient agreeing to participate in the study
• Patient affiliated to a social security scheme or benefiting from such a scheme

Exclusion Criteria:

• Viscosupplementation less than 6 months old
• Intra-articular corticosteroid injection less than 2 months old
• Inflammatory arthritis or active infectious of the knee studied
• History of surgery of the lower limb concerned
• Kellgren & Lawrence grades not defined
• Known hypersensitivity to hyaluronic acid or chondroitin sulfate
• Pregnant or breastfeeding women
• Patient under guardianship, curatorship or judicial safeguard
• Patient participating in another clinical investigation, at the time of inclusion

Patients with knee osteoarthritis